Profile data is unavailable for this security.
About the company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. The Company does this by providing financing, licensing its technologies or both. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled several United States Food and Drug Administration (FDA)-approved products, including Gilead's Veklury, Amgen's Kyprolis, Baxter International's Nexterone, Melinta Therapeutics' Baxdela and Sage Therapeutics' Zulresso. Its technologies also include HepDirect, LTP and BEPro Technology Platform, SUREtechnology Platform (owned by Selexis), and Pelican Expression Technology. It has established multiple alliances, licenses and other business relationships with various pharmaceutical companies including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences and Baxter International.
- Revenue in USD (TTM)152.42m
- Net income in USD45.24m
- Incorporated1987
- Employees58.00
- LocationLigand Pharmaceuticals Inc3911 Sorrento Valley Blvd, Suite 110SAN DIEGO 92121United StatesUSA
- Phone+1 (858) 550-7500
- Fax+1 (302) 636-5454
- Websitehttps://www.ligand.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Innoviva Inc | 352.75m | 64.59m | 1.20bn | 112.00 | 27.84 | 1.79 | 11.48 | 3.40 | 0.6879 | 0.6879 | 4.78 | 10.68 | 0.2916 | 1.14 | 4.44 | 3,149,509.00 | 5.34 | 26.24 | 5.98 | 28.53 | 87.93 | -- | 18.31 | 76.84 | 1.64 | 1.93 | 0.4011 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
| Ocular Therapeutix Inc | 61.44m | -174.34m | 1.37bn | 267.00 | -- | 3.91 | -- | 22.28 | -1.30 | -1.30 | 0.4442 | 2.25 | 0.1883 | 2.48 | 2.28 | 230,116.10 | -53.42 | -46.70 | -59.98 | -54.18 | 90.59 | 89.36 | -283.75 | -228.65 | 12.94 | -27.52 | 0.1615 | -- | 13.49 | 96.60 | -13.65 | -- | 26.37 | -- |
| Harrow Inc | 169.14m | -33.41m | 1.51bn | 315.00 | -- | 26.07 | -- | 8.90 | -0.9408 | -0.9408 | 4.76 | 1.63 | 0.5305 | 4.86 | 4.69 | 536,946.10 | -10.48 | -10.86 | -12.74 | -12.71 | 72.56 | 70.75 | -19.75 | -15.35 | 1.44 | -0.3529 | 0.7635 | -- | 46.95 | 25.77 | -73.30 | -- | 143.88 | -- |
| Immunocore Holdings PLC - ADR | 296.55m | -47.11m | 1.62bn | 497.00 | -- | 4.29 | -- | 5.47 | -0.9494 | -0.9494 | 5.88 | 7.55 | 0.3593 | 0.541 | 5.68 | 596,681.90 | -5.71 | -27.55 | -7.45 | -36.82 | 99.38 | -- | -15.89 | -97.12 | 3.76 | -- | 0.5373 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.77bn | 244.00 | -- | 7.49 | -- | 13.67 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.87bn | 246.00 | 15.52 | 3.13 | 12.73 | 2.74 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.91bn | 3.00k | -- | 1.04 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 1.99bn | 652.00 | 33.82 | 1.98 | 13.95 | 3.06 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.11bn | 58.00 | 45.97 | 2.49 | 26.10 | 13.83 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.13bn | 1.76k | 14.67 | 2.93 | 10.10 | 2.95 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Twist Bioscience Corp | 312.97m | -208.73m | 2.44bn | 923.00 | -- | 5.12 | -- | 7.80 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.52bn | 167.00 | 18.04 | 3.82 | 13.99 | 5.48 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.60bn | 7.70k | -- | -- | 32.33 | 0.9712 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.83bn | 314.00 | 740.18 | 10.96 | 317.66 | 12.46 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Data as of Nov 21 2024. Currency figures normalised to Ligand Pharmaceuticals Inc's reporting currency: US Dollar USD
55.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 30 Sep 2024 | 2.76m | 15.13% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 1.94m | 10.61% |
| Janus Henderson Investors US LLCas of 30 Sep 2024 | 1.00m | 5.48% |
| Macquarie Investment Management Business Trustas of 30 Sep 2024 | 887.28k | 4.86% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 707.41k | 3.87% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 669.41k | 3.66% |
| Stephens Investment Management Group LLCas of 30 Sep 2024 | 618.70k | 3.39% |
| Congress Asset Management Co. LLPas of 30 Sep 2024 | 604.04k | 3.31% |
| Chicago Capital LLCas of 30 Sep 2024 | 545.82k | 2.99% |
| St. Denis J. Villere & Co. LLCas of 30 Sep 2024 | 474.86k | 2.60% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
